Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Gastrointestinal 1Breast 1

Conditions

Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Melanoma 3Medulloblastoma 3Ependymoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 30Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × 1-methyltryptophan × Clear all
NCT02073123 2026-05-29

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Lumos Pharma

Phase 1/2 Completed
131 enrolled 23 charts
Dermatologic

Melanoma

NCT03301636 2022-09-27

NLG2107

Lumos Pharma

Phase 2 Terminated
21 enrolled 11 charts
Dermatologic

Melanoma

NCT00739609 2020-05-28

D-1MT

Lumos Pharma

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡